SCYNEXIS (SCYX) Stock Analysis
NASDAQHealthcareMedical - Pharmaceuticals
What SCYNEXIS does
SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ.
Key metrics
ETFs linked to SCYX
Broad-market and Healthcare sector ETFs an investor holding SCYNEXIS is often also exposed to. Open an ETF page to see its actual top holdings.
PortView Portfolio Insights
PortView analyzes how SCYX fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.
Analyze SCYX in PortView →Similar companies
Frequently asked questions
- What is the ticker symbol for SCYNEXIS?
- SCYNEXIS trades under the ticker SCYX on NASDAQ.
- Which exchange is SCYX listed on?
- SCYX is listed on NASDAQ.
- What sector does SCYNEXIS operate in?
- SCYNEXIS is classified in the Healthcare sector (Medical - Pharmaceuticals industry).
- How can PortView help analyze SCYX in a portfolio?
- PortView shows SCYX's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.
The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.